Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Flanagan, Jack U ^a,b   Yosaatmadja, Yuliana ^c   Teague, Rebecca M ^c   Chai, Matilda Z L ^c   Turnbull, Andrew P ^d   Squire, Christopher J ^b,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE 1C3; ARYLPROPIONIC ACID DERIVATIVE; EFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MECLOFENAMIC ACID; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; SULINDAC; UNCLASSIFIED DRUG; ZOMEPIRAC;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; MOLECULAR DOCKING; PROTEIN FAMILY;

3-HYDROXYSTEROID DEHYDROGENASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FLUFENAMIC ACID; FLURBIPROFEN; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IBUPROFEN; INDOMETHACIN; MECLOFENAMIC ACID; MEFENAMIC ACID; NAPROXEN; SULINDAC; TOLMETIN;

EID: 84865469114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043965     Document Type: Article

References (56)

1. Dufort I, Rheault P, Huang X-F, Soucy P, Luu V, (1999) Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140: 568-574.
2. Byrns MC, Duan L, Lee SH, Blair IA, Penning TM, (2010) Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol 118: 177-187.
3. Sharma KK, Lindqvist A, Zhou XJ, Auchus RJ, Penning TM, et al. (2006) Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol Cell Endocrinol 248: 79-86.
4. Suzuki-Yamamoto T, Nishizawa M, Fukui M, Okuda-Ashitaka E, Nakajima T, et al. (1999) cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett 462: 335-340.
5. Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, et al. (1998) Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem 124: 940-946.
6. Koda N, Tsutsui Y, Niwa H, Ito S, Woodward DF, et al. (2004) Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS. Arch Biochem Biophys 424: 128-136.
7. Butler R, Mitchell SH, Tindall DJ, Young CY, (2000) Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 11: 49-61.
8. Jabbour HN, Sales KJ, Boddy SC, Anderson RA, Williams AR, (2005) A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 146: 4657-4664.
9. Nakata S, Yoshida T, Shiraiahi T, Horinaka M, Kouhara J, et al. (2006) 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Therapeutics 5: 1827-1835.
10. Ray DM, Akbiyik F, Phipps RP, (2006) The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J Immunol 177: 5068-5076.
11. Scher JU, Pillinger MH, (2009) The anti-inflammatory effects of prostaglandins. J Investig Med 57: 703-708.
12. Diers AR, Dranka BP, Ricart KC, Oh JH, Johnson MS, et al. (2010) Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy. Biochem J 430: 69-78.
13. Khanim FL, Hayden RE, Birtwistle J, Lodi A, Tiziani S, et al. (2009) Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One 4: e8147.
14. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454.
15. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033-5041.
16. Penning TM, Jin Y, Rizner TL, Bauman DR, (2008) Pre-receptor regulation of the androgen receptor. Mol Cell Endocrinol 281: 1-8.
17. Smuc T, Rizner TL, (2009) Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 301: 74-82.
18. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70: 1573-1584.
19. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, et al. (2010) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70: 1256-1264.
20. Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stal O, (2006) 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res 66: 11471-11477.
21. Lin H-K, Steckelbroeck S, Fung K-M, Jones AN, Penning TM, (2004) Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69: 795-801.
22. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, et al. (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12: 101-107.
23. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
24. Komoto J, Yamada T, Watanabe K, Takusagawa F, (2004) Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43: 2188-2198.
25. Komoto J, Yamada T, Watanabe K, Woodward DF, Takusagawa F, (2006) Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. Biochemistry 45: 1987-1996.
26. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, White SA, (2004) Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the non-steroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 64: 1802-1810.
27. Qiu W, Zhou M, Labrie F, Lin SX, (2004) Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol Endocrinol. 18: 1798-1807.
28. Qiu W, Zhou M, Mazumdar M, Azzi A, Ghanmi D, et al. (2007) Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 282: 8368-8379.
29. Adeniji AO, Twenter BM, Byrns MC, Jin Y, Chen M, et al. (2012) Development of potent and selective inhibitors of aldo-keto reductase 1C2 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem 55: 2311-2323.
30. Jackson VJ, Yosaatmadja Y, Flanagan JU, Squire CJ, (2012) Structure of AKR1C3 with 3-phenoxybenzoic acis bound. Acta Cryst. F68: 409-413.
31. Schlegel BP, Jez JM, Penning TM, (1998) Mutagenesis of 3R-hydroxysteroid dehydrogenase reveals a "push-pull". mechanism for proton transfer in aldo-keto reductases, Biochemistry 37: 3538-3548.
32. Byrns MC, Penning TM, (2009) Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact 178: 221-227.
33. Byrns MC, Jin Y, Penning TM, (2011) Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J Steroid Biochem Mol Biol 125: 95-104.
34. Byrns MC, Steckelbroeck S, Penning TM, (2008) An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 75: 484-493.
35. Blobaum AL, Marnett LJ, (2007) Structural and functional basis of cyclooxygenase inhibition. J Med Chem 50: 1425-1441.
36. Wolfe MM, Lichtenstein DR, Singh G, (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.
37. Rainsford KD, (2007) Anti-inflammatory drugs in the 21st century. Subcell Biochem 42: 3-27.
38. Khan MN, Lee YS, (2011) Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy. Med Res Rev 31: 161-201.
39. McPhillips TM, McPhillips SE, Chiu HJ, Cohen AE, Deacon AM, et al. (2002) Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Rad 9: 401-406.
40. Kabsch W, (2010) XDS. Acta Cryst D66: 125-132.
41. Evans P, (2006) Scaling and assessment of data quality. Acta Cryst. D62: 72-82.
42. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J. Appl. Cryst. 40: 658-674.
43. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Cryst. D66: 486-501.
44. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Cryst D67: 355-367.
45. Schuettelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Cryst. D60: 1355-1363.
46. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, et al (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Cryst. D66: 12-21.
47. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, et al. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384: 644-648.
48. Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, et al. (2010) Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem 285: 34950-34959.
49. Duggan KC, Hermanson DJ, Musee J, Prusakiewicz JJ, Scheib JL, et al. (2011) (R)-Profens are substrate-selective inhbitors of endocannabinoid oxygenation by COX-2. Nature Chemical Biology. doi: 10.1038/NChemBio.663.
50. Bishay P, Schmidt H, Marian C, Häussler A, Wijnvoord N, et al. (2010) R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One 5: e10628.
51. Andrews P, Zhao X, Allen J, Li F, Chang M, (2008) A comparison of the effectivness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 61: 203-214.
52. Wynne S, Djakiew D, (2010) NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 induction via the p38 MAPK-p75(NTR) pathway. Mol Cancer Res 8: 1656-1664.
53. Penning TM, Mukharji I, Barrows S, Talalay P, (1984) Purification and properties of a 3 alpha-hydroxysteroid dehydrogenase of rat liver cytosol and its inhibition by anti-inflammatory drugs. Biochemical J 222: 601-611.
54. Olsson MH, Sondergaard CR, Rostkowski M, Jensen JH, (2011) PROPKA: consistent treatment of internal and surface residues in empirical pKa predictions. Journal of Chemical Theory and Computation 2: 525-537.
55. Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, et al. (2011) Docking performances of fragments and druglike compounds. J Med Chem 54: 5422-5431.
56. Adeniji AO, Twenter BM, Byrns MC, Jin Y, Winkler JD, et al. (2011) Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett 21: 1464-1468.